Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy
These findings support the need for E2 monitoring in women receiving fulvestrant therapy to better assess E2 status and its association with treatment efficacy.
Authors
- Zhongyu Yuan (ORCID: https://orcid.org/0000-0002-2920-9671)
- Qiufan Zheng (ORCID: https://orcid.org/0000-0003-3752-8506)
- Yong-Yi Zhong
- Xiaoming Xie (ORCID: https://orcid.org/0000-0003-0687-4238)
- Yanxia Shi (ORCID: https://orcid.org/0000-0002-9658-0032)
- Xin An (ORCID: https://orcid.org/0000-0003-0683-5511)
- Xingping Wu (ORCID: https://orcid.org/0000-0002-3182-688X)
- Meiting Chen (ORCID: https://orcid.org/0000-0002-7195-1300)
- Cong Xue (ORCID: https://orcid.org/0000-0003-3558-8572)
- Yi Yang (ORCID: https://orcid.org/0000-0001-9898-0366)
- Peng Liu (ORCID: https://orcid.org/0000-0001-7150-6365)
- Xi Wang (ORCID: https://orcid.org/0000-0002-7572-6354)
- Fei Xu (ORCID: https://orcid.org/0009-0000-0815-7836)
- Yanling Wen
- Jun Tang (ORCID: https://orcid.org/0000-0002-9788-8389)
- Shuqin Dai (ORCID: https://orcid.org/0000-0002-6776-8466)
- Shusen Wang
- Jiajia Huang
- Xi-Wen Bi
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf403
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China